(XPHYF) Could Be Inching Towards A Potential Breakout, Now Up Approximately 10%

XPHYF is continuing to heat up... New Update: (XPHYF) Could Be Inching Towards A Potential Breakout, Now Up Approximately 10% June 1st FierceAnalyst Reader, XPHYF is continuing to heat up... Hitting a high of $1.90, XPHYF is now up approximately 10%. Is $2.00 right around the corner? As I mentioned previously, the last time I brought this profile to your attention it opened at $1.87 and ran to a high of $2.14. Continue to do your research on XPHYF and get it on your radar quickly. ----- Lockdown has become tiresome. Sure, we're starting to see some light at the end of the tunnel, but is it really close or far away? Even with some hope on the horizon, are you tired of not getting back to the "status quo" before the pandemic hit? Listen. You're not alone. We now have access to vaccines and as far as we can tell they appear to be working. That said, this health crisis looks like it could be far from over. For millions like me, this health predicament has become personal as I've seen loved ones get sick and friends of friends alike. Rapid testing could be a key component to getting the world up and running again while giving us the peace of mind to start living our lives at 100% capacity. XPhyto Therapeutics Corp. (XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psych-e-delic compounds and can-na-bin-oids. The company has a strong pipeline of drugs and diagnostic tests in development and could be well-positioned in the global rapid test market, projected to reach USD $39.1Bn by 2023 with a CAGR of 8.9%. (source 1) XPHYF Pipeline As you can see above, this company is not messing around and has been hard at work advancing multiple diagnostic products/drugs/treatments towards completion. None may be more important than the one at the top, Rapid RT-PCR. CV-19 RT-PCR Diagnostic Test - Rapid test in 25 minutes - 5 min hands-on time and 20 mins reaction only - Point of care diagnostic device - for use with minimal lab equipment - Low detection limit - diagnostic reliability of PCR tests - Cost-effectiveness - enables broad testing - Easily accessible ----- And, major news regarding this diagnostic product and more could become major catalysts for this company moving forward. Here's what you need to know: #1. Potential XPHYF Catalyst - European Approval News XPhyto announces European Approval for 25 Minute CV19 PCR Test - CE Mark received for in vitro diagnostic (IVD) test for the detection of SA-RS-Co-V-2 - Rapid results with ease of use - single 20-minute PCR cycle plus 5-minute detection process - High sensitivity - 104.73 c/PCR limit of detection with 95% confidence interval - High specificity - zero cross-reactivity on 19x respiratory infectious disease panel - High robustness - no impact on results from minor changes in process parameters - 100% repeatability and laboratory precision observed - Sales launch in Europe planned for April 2021 VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SA-RS-Co-V-2 (CV-19) RT-PCR test system ("CV-ID Lab"). CV-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test. "Our test is one of the fastest PCR-based CV19 tests currently approved. With a sample collection to result time of 25 minutes, CV-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic," said Hugh Rogers, CEO and Director of XPhyto. "CV-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings." [...] During validation of the assay, the limit of detection for SA-RS-Co-V-2 RNA was determined to be 104.73 c/PCR within a 95% confidence interval. Specificity of 100% against 19 other pathogens of serious respiratory infections was demonstrated on a respiratory verification panel. Precision was determined through evaluation of variance of the analysis results due to random deviations, a repeatability/intra-assay precision evaluation (same lab, user, equipment, etc.), and a laboratory precision evaluation (different lab, user, equipment, etc.). Robustness was measured by evaluation of the impact of minor changes on process parameters (transport medium, PCR cycler model, ramp rate, template volume, hybridization mixing ratio, etc.). The validation studies were carried out accordingly to ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology and VQ-015 Validation of Methods, European Medicines Agency. The quality management system was in accordance with EN ISO 13485: 2016 and EN ISO 9001: 2015. XPhyto is currently in discussions with various potential distribution and wholesale partners as well as potential licensees. The sales launch in Europe is targeted for April 2021. The company will provide further information and updates in due course. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the CV19 pandemic. [Read the full article here.]( ----- BREAKING: As millions are struggling with Parkinson’s Disease, health professionals fear we could be on the cusp of an epidemic... That’s according to Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, as reported by The Guardian.(2) “Parkinson’s is already the fastest-growing neurological disorder in the world; in the US, the number of people with Parkinson’s has increased 35% the last 10 years," says Dorsey, and “We think over the next 25 years it will double again.”(2) Unfortunately, there is no cure – at least not yet. However, there may be help on the way. In fact, XPhyto Therapeutics’ subsidiary, Vektor Pharma’s transdermal form of dopamine treatment – Rotigotine — could help ease motor symptoms of Parkinson’s, and potentially help with several non-motor symptoms.(3) After all, according to a report from CNS Drugs: “Motor and non-motor symptoms (NMS) have a substantial effect on the health-related quality of life (QoL) of patients with Parkinson’s disease (PD). Transdermal therapy has emerged as a time-tested practical treatment option, and the rotigotine patch has been used worldwide as an alternative to conventional oral treatment for PD.” That's why this recent news about a successful human pilot study could be major news for XPHYF in the short term. Check it out: #2. Potential XPHYF Catalyst - [XPhyto Provides Update on Drug Formulation and Development Business]( ----- #3. Potential XPHYF Catalyst - Test Offered For Sale In Germany XPhyto Rapid Point-of-Care CV-19 PCR Test Offered for Sale in Germany - Rapid 25-minute point-of-care CV19 PCR test available for purchase in Germany commencing May 25, 2021 - Volume based pricing competitive with other CV19 PCR test products on the market - Initial manufacturing capacity secured, additional capacity to increase based on demand VANCOUVER, BC and MEMMINGEN, GERMANY / ACCESSWIRE / May 20, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its distribution, storage and logistics partner, Max Pharma GmbH ("Max Pharma"), will launch the sale of its 25-minute SA-RS-C-oV-2 (C19) RT-PCR test system ("CV-ID Lab") in Germany next week. CV-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test. CV-ID Lab is a rapid RT-PCR test for the qualitative detection of SA-RS-Co-V-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. CV-ID Lab requires only a 20-minute PCR run time without prior RNA extraction. Following the RT-PCR process, the SA-RS-C-oV-2 virus is detected on a test chip and the results can be read visually within 5 minutes, combining the speed of an antigen test with the accuracy of a PCR test. "CV-ID Lab provides diagnostic level accuracy in minutes at the point-of-care. It is a specialized product that is designed to fill the market gap between disposable antigen tests and centralized automated PCR systems," says Wolfgang Probst, COO and director of XPhyto. "Examples of target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results." [...] The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the C19 pandemic. [Read the full article here.]( ----- #4. Potential XPHYF Catalyst - Pursuing Market Access In Israel XPhyto Pursues Market Access in Israel for its CV19 PCR Rapid Test - XPhyto delivered 2,000 of its 25-minute PCR tests to Israeli distributor for clinical evaluation and regulatory approval - Potential customers include government institutions, private healthcare providers and neighboring countries VANCOUVER, BC / ACCESSWIRE / April 28, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has delivered 2,000 of its rapid 25-minute PCR tests ("CV-ID Lab") to an established medical distributor in Israel for clinical evaluation of CV-ID Lab for the purpose of commercial regulatory approval and potential product distribution. Based on the European CE-IVD approval of CV-ID Lab, announced by the Company on March 18, 2021, CV-ID Lab will be evaluated by the Medical Device Division of the Israeli Ministry of Health (AMAR) for the purpose of securing Israeli regulatory approval. Israel recognizes several international medical device certifications including the European CE-IVD mark. The clinical evaluation process is expected to be complete in less than 90 days and will form the basis for commercial approval of CV-ID Lab in Israel. The Israeli distributor markets and distributes a range of medical products, including diagnostics, in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. "We are excited by the opportunity to expand potential distribution beyond Germany. We are building strong partnerships around the world and Israel is a leading nation for CV-19 management and research," said Hugh Rogers, CEO and Director of XPhyto. "We expect that rapid and accurate diagnostic testing will remain a primary tool for pandemic management and monitoring for many years to come." [...] The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the CV-19 pandemic. [Read the full article here.]( ----- #5. Potential XPHYF Catalyst - Signing Of German Distribution, Storage And Logistics Agreement XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute CV19 PCR Test VANCOUVER, BC / ACCESSWIRE / April 21, 2021 /XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with an established German pharmaceutical wholesaler and service provider (the "Distributor") for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its 25-minute SA-RS-Co-V-2 (CV-19) RT-PCR test system ("CV-ID Lab"). CV-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test. Pursuant to the Agreement, the Distributor will distribute, store and deliver CV-ID Lab test kits according to the product specifications and all applicable regulations to XPhyto's customers. In addition, the Distributor will provide the documentation and fulfillment of storage obligations, the fulfillment of reporting and notification obligations, and the processing of any returned products. The obligations and services to be rendered under the Agreement satisfy all of the logistical and regulatory requirements for the commercial sale of CV-ID Lab in Germany. "With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of CV-ID Lab," said Hugh Rogers, CEO and Director of XPhyto. "The Company's commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales." [...] The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the CV-19 pandemic. [Read the full article here.]( ----- XPhyto Therapeutics Corp. World-class Management Team ----- Recap: Top 5 Potential XPHYF Catalysts 1. European Approval 2. Drug Formulation And Development Business Update 3. Test Offered For Sale In Germany 4. Pursuing Market Access In Israel 5. Signing Of German Distribution, Storage And Logistics Agreement ----- Coverage is officially initiated on XPHYF. Also, while you have time now, do this: If there are any more updates today, I'll get them out to you quickly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer Remember that the best source for full disclosure about the company is the company itself, SEDAR or CSE profile pages for regulatory filings and news releases. [source 1]( [source 2]( [source 3]( I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 5/7/21 and ending on 5/10/21 to publicly disseminate information about (XPHYF) via Website, Email and SMS. We were paid seven thousand five hundred USD via ACH. We own zero shares of (XPHYF). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Investing Channel, StockWireNews has been hired for a period beginning on 5/7/21 and ending on 5/10/21 to publicly disseminate information about (XPHYF) via Website, Email and SMS. We have been paid forty thousand USD via bank wire transfer. We own zero shares of (XPHYF). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 5/28/21 and ending on 6/2/21 to publicly disseminate information about (XPHYF) via Website, Email and SMS. We were paid five thousand USD via ACH. We own zero shares of (XPHYF). To date we have been compensated a total of twelve thousand five hundred USD via ACH to disseminate information about (XPHYF). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Investing Channel, StockWireNews has been hired for a period beginning on 5/28/21 and ending on 6/2/21 to publicly disseminate information about (XPHYF) via Website, Email and SMS. We have been paid thirty thousand USD via bank wire transfer. We own zero shares of (XPHYF). To date we have been compensated a total of seventy thousand USD via bank wire transfer to disseminate information about (XPHYF). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net